Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2019

View Archived Issues

Recruitment ongoing in Immunocore's first-in-human study of IMC-C103C

Boston Pharmaceuticals begins phase IIa study of BOS-589 in IBS-D

Norovirus' bright side

Beactica receives grant to advance research on preclinical candidate BEA-17 for glioblastoma

BeiGene, SpringWorks form MapKure to develop next-generation RAF kinase inhibitor BGB-3245

Phase I/II study of nivolumab plus radical surgery in microsatellite stable LARC

Muscle CB1R regulates whole-body metabolism and physical performance, novel mouse model shows

Cellular lung map gives asthma, other insights

Recruitment ongoing in phase I study of VSV-IFNb-TYRP1 for the treatment of melanoma

Arch Biopartners initiates phase I study of Metablok

Positive early safety and efficacy results of phase I/II study of nomacopan in AKC

Updated positive results for phase Ib study of resiniferatoxin in knee osteoarthritis pain

Apatinib monotherapy shows promising efficacy and manageable toxicities in mCRC

Durvalumab in combination with R-CHOP shows promising response rates in high-risk DLBCL

Abatacept misses primary endpoint in Sjogren's syndrome in phase III study

Step Pharma discovers new CTP synthase 1 inhibitors

5-HT7 antagonists patented by KAIST, KIST

Servier, Vernalis disclose ubiquitin carboxyl-terminal hydrolase 7 inhibitors

Disulfiram and copper with concurrent RT and temozolomide for glioblastoma: phase I/II trial

Janssen presents compound for respiratory syncytial virus infections

New Janus kinase inhibitors synthesized at Korea Pharma

Loss of NFASC NF186 isoform tied to hereditary ataxia

New phase I study evaluates TBX-3400 in stage III/IV melanoma resistant or refractory to immune CPIs

GSK initiates phase III trials of GSK-3196165 in moderate to severely active rheumatoid arthritis

DiaMedica reports phase Ib interim data on DM-199 in chronic kidney disease

PCYT2 gene mutations seen to cause neurological disorder